Technical Analysis for SGTX - Sigilon Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | N/A | Flat |
| Historical SGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 3.81% | |
| Hot IPO Pullback | Bullish Swing Setup | 3.81% | |
| Narrow Range Bar | Range Contraction | 3.81% | |
| NR7 | Range Contraction | 3.81% | |
| NR7-2 | Range Contraction | 3.81% | |
| Doji - Bullish? | Reversal | 3.81% | |
| Wide Bands | Range Expansion | 3.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | about 9 hours ago | |
| Rose Above 10 DMA | about 10 hours ago | |
| Up 5% | about 11 hours ago | |
| Hot IPO Pullback Entry | about 12 hours ago | |
| 1,2,3, Pullback Entry | about 12 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Disease Diabetes Health Sciences Hemophilia Chronic Disease Chronic Diseases Hemophilia A Mucopolysaccharidosis Haemophilia Mucopolysaccharidosis Type
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Disease Diabetes Health Sciences Hemophilia Chronic Disease Chronic Diseases Hemophilia A Mucopolysaccharidosis Haemophilia Mucopolysaccharidosis Type
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 54.32 |
| 52 Week Low | 22.0 |
| Average Volume | 140,417 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 37.64 |
| 10-Day Moving Average | 35.60 |
| Average True Range | 4.63 |
| ADX | 43.28 |
| +DI | 26.79 |
| -DI | 12.32 |
| Chandelier Exit (Long, 3 ATRs ) | 40.43 |
| Chandelier Exit (Short, 3 ATRs ) | 40.19 |
| Upper Bollinger Band | 45.79 |
| Lower Bollinger Band | 29.48 |
| Percent B (%b) | 0.37 |
| BandWidth | 43.32 |
| MACD Line | 0.69 |
| MACD Signal Line | 1.47 |
| MACD Histogram | -0.7811 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.02 | ||||
| Resistance 3 (R3) | 39.10 | 37.99 | 38.42 | ||
| Resistance 2 (R2) | 37.99 | 37.09 | 37.95 | 38.22 | |
| Resistance 1 (R1) | 36.73 | 36.53 | 37.36 | 36.65 | 38.03 |
| Pivot Point | 35.62 | 35.62 | 35.94 | 35.58 | 35.62 |
| Support 1 (S1) | 34.36 | 34.72 | 34.99 | 34.28 | 32.89 |
| Support 2 (S2) | 33.25 | 34.16 | 33.21 | 32.70 | |
| Support 3 (S3) | 31.99 | 33.25 | 32.50 | ||
| Support 4 (S4) | 31.91 |
